KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Current Deferred Revenue (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Current Deferred Revenue for 10 consecutive years, with $15.8 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue rose 310.17% to $15.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.8 million through Dec 2025, up 310.17% year-over-year, with the annual reading at $15.8 million for FY2025, 310.17% up from the prior year.
  • Current Deferred Revenue hit $15.8 million in Q4 2025 for CRISPR Therapeutics AG, up from $1.3 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $15.8 million in Q4 2025 to a low of $1.0 million in Q4 2021.
  • Historically, Current Deferred Revenue has averaged $4.4 million across 5 years, with a median of $3.5 million in 2023.
  • Biggest five-year swings in Current Deferred Revenue: crashed 91.71% in 2021 and later soared 1116.62% in 2022.
  • Year by year, Current Deferred Revenue stood at $1.0 million in 2021, then skyrocketed by 1116.62% to $12.3 million in 2022, then tumbled by 66.63% to $4.1 million in 2023, then decreased by 6.33% to $3.8 million in 2024, then surged by 310.17% to $15.8 million in 2025.
  • Business Quant data shows Current Deferred Revenue for CRSP at $15.8 million in Q4 2025, $1.3 million in Q3 2025, and $2.1 million in Q2 2025.